Brazikumab: Data from P2b/3 INTREPID trial (NCT03759288) for Crohn's disease in 2021 or later (AstraZeneca) - Jul 30, 2020 - H1 2020 Results: Data from P3 trial (NCT03961815) for Crohn's disease in 2021 or later
P2/3 data • P3 data • Crohn's disease • Inflammatory Bowel Disease
|